MedTrace Logo

Urinary Neutrophil Gelatinase-Associated Lipocalin (uNGAL) in Invasive Cardiology

NCT01612117 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 244

Last updated 2014-05-28

No results posted yet for this study

Summary

Diagnosis of acute kidney injury (AKI) relies on a late marker, namely serum creatinine (SCr). New biomarkers are considered for early and sensitive detection of CIN. In particular, uNGAL has been used for early detection of AKI in the emergency department, after cardiopulmonary bypass or following CM administration.

This study will be conducted to assess the possible value of urinary Neutrophil Gelatinase-Associated Lipocalin (uNGAL) as an early detector of contrast-induced nephropathy (CIN) in a large sized cohort of patients undergoing percutaneous coronary procedures (PCP) and whether or not uNGAL correlates with the volume of contrast medium (CM) used.

Conditions

  • Renal Failure

Sponsors & Collaborators

  • University of Freiburg

    lead OTHER

Principal Investigators

  • Stephane Cook, MD · University Fribourg

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-11-30
Primary Completion
2012-02-29
Completion
2012-02-29

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01612117 on ClinicalTrials.gov